Stock Code: 002772 stock abbreviation: Tianshui Zhongxing Bio-Technology Co.Ltd(002772) Announcement No.: 2022-008 bond Code: 128026 bond abbreviation: Zhongxing convertible bonds
Tianshui Zhongxing Bio-Technology Co.Ltd(002772)
Performance forecast for 2021
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
1、 Expected performance of the current period
1. Performance forecast period: January 1, 2021 to December 31, 2021
2. Performance forecast
□ turning losses into profits □ rising in the same direction ☑ Descending in the same direction
The current reporting period of the project is the same period of last year
Earnings attributable to listed companies: 43 million yuan – 63 million yuan
East’s net profit: 188959300 yuan, down 66.66% – 77.24% over the same period last year
Profit after deducting non recurring profit and loss: 26 million yuan – 38 million yuan
Net profit after: 147278300 yuan, down 74.20% – 82.35% over the same period of last year
Basic earnings per share: 0.11 yuan / share – 0.17 yuan / share; earnings per share: 0.56 yuan / share
2、 Communication with accounting firms
The financial data related to this performance forecast is the preliminary calculation result of the company’s financial department and has not been pre audited by an accounting firm. The company has made pre communication with the annual report audit accounting firm on matters related to the performance forecast, and there is no difference between the company and the accounting firm on the performance forecast in the reporting period.
3、 Reasons for changes in performance forecast
Affected by the trade of bulk goods, the purchase price of raw materials for edible fungus production increased as a whole, and the product cost increased significantly; In the post epidemic era, the consumption in the downstream market of edible fungi is weak, especially the sales price of Flammulina velutipes products remains low, and the market performance in the traditional peak sales season is poor; Repeated epidemics, rainstorms and other factors led to the scrapping of some batches of finished products and products in process.
4、 Other relevant instructions
This performance forecast is the preliminary calculation result of the company’s financial department. The specific financial data shall be subject to the data disclosed in the company’s 2021 annual report. Please make prudent decisions and pay attention to investment risks. It is hereby announced
Tianshui Zhongxing Bio-Technology Co.Ltd(002772) board of directors January 12, 2022
